ArticleFrontiers in oncology2026
Landscape of germline genetic alterations among non-western young male patients with cancer. Findings from The Jordanian exploratory cancer genetics study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early-onset cancers in males may indicate hereditary predisposition, yet real-world data on germline testing across diverse tumor types are limited. We evaluated the prevalence and spectrum of germline pathogenic/likely pathogenic (P/LP) variants in males diagnosed with cancer at ≤50 years. Consecutive male patients aged ≤50 years with newly diagnosed solid tumors enrolled in the Jordanian Exploratory Cancer Genetics (Jo-ECAG) program at the King Hussein Cancer Center underwent multigene panel germline testing irrespective of cancer type, stage, or family history. Patients were classified according to National Comprehensive Cancer Network (NCCN) testing criteria. P/LP and variant of uncertain significance (VUS) rates were analyzed by age, cancer type, and eligibility status. Among 652 patients (median age, 42 years), colorectal cancer predominated (48.0%), followed by gastric (6.7%), pancreatic (6.4%), and testicular (6.0%) cancers. Overall, 90 patients (13.8%) harbored P/LP variants and 216 (33.1%) had VUS. P/LP detection was higher among patients meeting NCCN criteria compared with those who did not (16.5% vs. 4.7%, p<0.001). Younger age was associated with higher yield (26.3% in ages 18-30 vs. 9.7% in 41-50 years, p<0.001). Colorectal cancer accounted for most pathogenic findings. Frequently altered genes included
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.